Evidence map›Paper›PMID 40075751›Full record

ReviewCancers2025

Evaluating the Impact of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on Interval and Secondary Debulking in Ovarian Cancer: A Systematic Review.

Dimitrios Tsolakidis, Dimitrios Kyziridis, Theodoros Panoskaltsis, Apostolos Kalakonas, Vasileios Theodoulidis, Kimon Chatzistamatiou, Dimitrios Zouzoulas, Antonios-Apostolos Tentes

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dimitrios Tsolakidis1st Department of Obstetrics & Gynecology, Aristotle University of Thessaloniki, 56429 Thessaloniki, Greece.
Dimitrios KyziridisSurgical Department of Peritoneal Surface Malignancy Program, EUROMEDICA Kyanous Stavros, 54636 Thessaloniki, Greece.ORCID 0000-0002-8139-3357
Theodoros PanoskaltsisSurgical Department of Peritoneal Surface Malignancy Program, EUROMEDICA Kyanous Stavros, 54636 Thessaloniki, Greece.ORCID 0000-0002-8651-0188
Apostolos KalakonasSurgical Department of Peritoneal Surface Malignancy Program, EUROMEDICA Kyanous Stavros, 54636 Thessaloniki, Greece.ORCID 0000-0001-9069-2183
Vasileios Theodoulidis1st Department of Obstetrics & Gynecology, Aristotle University of Thessaloniki, 56429 Thessaloniki, Greece.ORCID 0000-0002-7924-5224
Kimon Chatzistamatiou1st Department of Obstetrics & Gynecology, Aristotle University of Thessaloniki, 56429 Thessaloniki, Greece.ORCID 0000-0002-5357-4708
Dimitrios Zouzoulas1st Department of Obstetrics & Gynecology, Aristotle University of Thessaloniki, 56429 Thessaloniki, Greece.ORCID 0000-0003-2518-5657
Antonios-Apostolos TentesSurgical Department of Peritoneal Surface Malignancy Program, EUROMEDICA Kyanous Stavros, 54636 Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cytoreductive surgery (CRS)hyperthermic intraperitoneal chemotherapy (HIPEC)interval debulkingoncologic outcomesovarian canceroverall survival (OS)progression-free survival (PFS)secondary debulkingsurgical oncology

Identifiers

PMID40075751
PMCPMC11898962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.